What is the mariPOC® test system?

• A new point-of-care test system for acute infections
• First test system in the market for multianalyte POC testing
• Automated random-access antigen detection test
• For respiratory (swab, aspirate) and stool samples
• IVD-CE marked

Why to choose mariPOC® for acute infection diagnostics?

• Accuracy similar to central laboratory antigen tests
• Easy-to-use and short hands-on-time. The first result available in 20 minutes
• Automated results read-out
• Replaces conventional rapid and laboratory antigen tests
• Can be connected to laboratory information systems

What does the mariPOC® test system allow?

• Pathogen-specific diagnosis on time
• Accurate use of virus-specific drugs and antimicrobials
• In-patient cohorting
• Efficient control of patient flow
• Improved cost-effectiveness

ArcDia’s mariAST® is the most promising platform to tackle antibiotic resistance.

• Allows testing of antibiotic resistance directly from polymicrobial clinical samples
• Is rapid and easy to use
• Is fully automated
• Has a high capacity: 40 -100 samples per day
• Enables bringing AST and resistance testing in a point-of-care environment

mariAST® measures species-specific bacterial growth in real-time. mariAST® combines in-well culture and high-accuracy bacterial detection. The process yields an ID in only 20 minutes, and reports resistance results for strong positive inoculum in just 2 hours after sampling.

Pre-treatment

ArcDia’s mariAST® is based on ArcDia’s mariPOC® field-proven test system.

ArcDia’s platform:

• Is based on the proprietary TPX detection tecnology published in Nature Biotechnology in 2000
• Has been deployed in routine central lab and point-of-care settings since 2011
• Has been awarded e.g. Frost & Sullivan Point-of-Care Leadership Prize in 2014
• Whose sister technology, born and developed in ArcDia’s scientific founder’s lab in Finland, won The Nobel Prize in Chemistry in 2014